NYSCF Scientific Discovery Biobank

ConditionsALS Amyotrophic Lateral Sclerosis Alzheimer Disease Alzheimer Disease, Early Onset Alzheimer Disease, Late Onset Batten Disease Corticobasal Degeneration Dementia Frontotemporal Dementia Huntington Disease Lewy Body Disease Multiple Sclerosis Multiple System Atrophy Parkinson Disease Parkinson's Disease and Parkinsonism Progressive Supranuclear Palsy INAD Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Macular Degeneration Ovarian Cancer Cervical Cancer Uterine Cancer Vaginal Cancer Vulvar Cancer PTSD Post Traumatic Stress Disorder

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age30+

SponsorNew York Stem Cell Foundation Research Institute

About this trial

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 30 days or older.

Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control.

Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.

Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.

Disqualifiers

Wards of the state.

For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.

For prospective blood samples: history of coagulation disorder.

For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Trial population

Individuals with a diagnosis of one or more of the listed conditions. Individuals without a condition to serve as healthy controls (a comparison group for those with conditions).

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Biological Sample Collection
Other intervention
Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Treatment groups

10,000 Participants

are divided into 2 treatment groups

Group A: Affected Subjects1 intervention

Group B: Healthy Control1 intervention

Trial outcomes

Primary outcomes

Biobank

Establishment of a diverse repository of biological samples, stem cell lines, derivatives, and associated information to support investigations into the biology, etiology, manifestations, progression, risk factors, genetic underpinnings, and treatment of diseases, conditions, and traits.

Time frame

Baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

New York Stem Cell Foundation Research Institute

Lead sponsor

Source ClinicalTrials.gov

Apply now